Difference between revisions of "Part:BBa K1942000:Experience"
| Line 10: | Line 10: | ||
[[File:NJU_China_2016_iGEM_Parts_Description_K1942000_Figure_2.png]] | [[File:NJU_China_2016_iGEM_Parts_Description_K1942000_Figure_2.png]] | ||
| − | + | [[File:NJU_China_2016_iGEM_Parts_Description_K1942000_Figure_3.png]] | |
Figure 1. Protein quantitatively analysis of K-ras protein after transfection of KRAS siRNA | Figure 1. Protein quantitatively analysis of K-ras protein after transfection of KRAS siRNA | ||
Revision as of 11:14, 14 October 2016
Applications of BBa_K1942000
USAGE AND BIOLOGY
We packaged KRAS siRNA into exosomes by transfecting HEK293 cells with a plasmid expressing KRAS siRNA and then collected siRNA-encapsulated exosomes. When modified exosomes being intravenously injected, they will specifically recognize integrin receptors and fuse with Lung adenocarcinoma cells under the direction of the iRGD peptide. Once inside cells, KRAS siRNA will bind to KRAS mRNA through base-pairing and digest the mRNA, resulting in sharp decrease of K-ras in lung cancer cells. As a consequence, K-ras protein’s reduction and disturbed function will both result in the inhabitation of the proliferation of cancer cells, which ultimately have some therapeutic effects on lung cancer (non-small cell lung cancer in this case).
CHARACTERIZATION
To ensure the interference efficiency of anti-KRAS siRNA plasmid, we transfected it into human lung adenocarcinoma cell line A549 and then extracted protein from these cells to perform western blot. Significant down-regulation of K-ras can be observed in A549 cells treated with anti-KRAS siRNA, demonstrating that anti-KRAS siRNA has the gene silencing effect on lung cancer cells.
Figure 1. Protein quantitatively analysis of K-ras protein after transfection of KRAS siRNA
User Reviews
UNIQ4e2f73ac1facf3df-partinfo-00000000-QINU UNIQ4e2f73ac1facf3df-partinfo-00000001-QINU